Publication | Open Access

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma

Phase Ii TrialMedicineMelanomaImmunologyTumor ImmunityClinical TrialsMetastatic MelanomaImmune SurveillanceImmunotherapeuticsPharmacotherapyInterferon AlphaCancer TreatmentImmunotherapyOncologyRadiation OncologyHealth Sciences